Gilgamesh
Developer of Psychiatric Treatment Drugs
AbbVie
Innovative Drug Developer
Pharmaceutical giant AbbVie (AbbVie) is10AbbVie Inc. Acquires Neuroscience Startup for $XX BillionGilgamesh PharmaceuticalsThe news has recently caused a stir in the pharmaceutical industry. At the heart of this potential deal is the latter's product namedGM-2505The experimental antidepressant, itsIIaIn Phase Clinical Trials94%The remission rate is redefining major depressive disorder (MDD) The possibility boundary of treatment.
As a short-acting5-HT2AReceptor Agonist,GM-2505The innovation lies in the precise dual action targeting the serotonin system: both activating5-HT2AReceptors promote synaptic remodeling and enhance neural signal transmission by promoting serotonin release. The latest research from the Chinese Academy of Sciences reveals that this class of drugs works by binding to5-HT2AThe extended pocket of the receptor (EBP), Selective Activationβ-arrestinSignal pathway, achieving rapid antidepressant effects while avoiding hallucinogenic side effects, which is in contrast to the need for hallucinogens to simultaneously activateGProtein andβ-arrestinThe dual-channel mechanism forms a stark contrast.
This design enables it to24Within hours, the patient's Montgomery-Asperger Depression Scale (MADRS) Score Plummets18.5points, far exceeding the clinically meaningful improvement threshold (6-9points). Compare with currently mainstream rapid antidepressants--Johnson & JohnsonSpravato(Esketamine),GM-2505Demonstrates significant advantages.SpravatoAsNMDARAntagonists need to indirectly promote neural connection remodeling by blocking glutamate receptors, andGM-2505Directly targeting the serotonin system not only leads to faster effects but also limits post-administration monitoring time.2Within hours, highly compatible with existing hospital processes.
GilgameshPublishedIIaThe term data shows,40Moderate to SevereMDDThe patient underwent twoGM-2505 Treatment (10mgFirst Dose+15mg Next dose) after,MADRSScore decreased from baseline28Points,29The time-related remission rate soared to94%, and the efficacy persists until74There is no need to administer additional doses on the same day. This figure far exceedsSpravatoIn the performance of the latest clinical trials, the latter in28Days of treatment later,84mgThe remission rate in the dose group was only22.5%, and needs to be maintained weekly1-2Frequency of administration.
More crucially, the difference in safety.SpravatoDue to hallucinogenic and dissociative side effects,FDAIt is required to strictly limit the use in certified clinics, andGM-2505As a short-acting compound, no severe psychoactive side effects were reported in the trial. This characteristic makes it promising to break through the limitations of existing treatment scenarios and become more widely used in outpatient settings. Notably, the difference in duration of action between the two is particularly significant:GM-2505Two treatments can maintain for nearly3Months of efficacy, andSpravatoIf the administration is interrupted, the relapse rate in patients is4Within a week60%。
If this acquisition goes through, it will be AbbVie's second bet on the central nervous system field within a year. Following2024In October of the year14Billion-dollar acquisitionAliada TherapeuticsAnd its Alzheimer's disease-related assets after，Gilgamesh's pipeline fills in the crucial piece of the puzzle for depression treatment, exceptGM-2505Externally,NMDARAntagonistGM-1020（2...) and multiple preclinical neuroplasticity prodrugs, forming a complete layout from rapid relief to long-term neural repair.
AbbVie's strategic intent has been clearly revealed in its recent moves:2025Year5In the month, the company has justADARxReach billions of dollars in collaboration to develop the field of neurosciencesiRNATherapy, plus this time forGilgameshThe intention to acquire, build up "Small Molecule Drugs + Gene Therapy" The dual engines of neuroscience. This layout targets a rapidly growing market: although currentlyMDDThe scale of the drug market has not been disclosed, but the overall field of psychiatric treatment is showing vigorous growth. The market for schizophrenia drugs alone is expected to grow from2024Year of81.9Billion USD increased to2030Year112billion USD, with a compound annual growth rate of5.6%。
Neuroplasticity agents, as a new generation of non-hallucinogenic therapies, are becoming the focus of capital pursuit. Unlike psychedelic-derived drugs, these agents can promote neural connection regeneration without causing alterations in mental state. AbbVie has been involved early on.2024Year5Monthly6500Million-dollar upfront payment to lock in the partnership, and now the acquisition is being increased. Clearly, the aim is to seize the first-mover advantage in this cutting-edge field.
The transaction still holds uncertainties, butGilgameshThe potential of the pipeline has become obvious.GlobalDataData show,MDDField2Drug Periodphase transitionSuccess rate only39%, andGM-2505By virtue ofAIDrivenEnkiduR&D platform, is expected to break through this "Death Valley". This deal is worth10A Billion-Dollar Gamble That Could Reshape the Future of Depression Treatment
